P
Purple Biotech Ltd
TASE:PPBT
Purple Biotech Ltd
TASE:PPBT
Price:
20 ILS
-10.31%
Market Closed
Updated:
May 5, 2024
Purple Biotech Ltd
Cash from Operating Activities
|
Purple Biotech Ltd
Cash from Operating Activities Peer Comparison
Comparables:
T
TEVA
TARO
I
INCR
MDWD
R
REKA
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Cash from Operating Activities
-$19.9m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cash from Operating Activities
$1.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Cash from Operating Activities
$142.9m
|
CAGR 3-Years
48%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-9%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Cash from Operating Activities
-₪3.4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-2%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Cash from Operating Activities
-$10.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cash from Operating Activities
₪30.7m
|
CAGR 3-Years
28%
|
CAGR 5-Years
22%
|
CAGR 10-Years
15%
|
See Also
What is Purple Biotech Ltd's Cash from Operating Activities?
Cash from Operating Activities
-16.7m
USD
-16.7m
USD
Based on the financial report for Dec 31, 2022, Purple Biotech Ltd's Cash from Operating Activities amounts to -16.7m USD.
What is Purple Biotech Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-14%
-14%
Over the last year, the Cash from Operating Activities growth was -10%. The average annual Cash from Operating Activities growth rates for Purple Biotech Ltd have been -44% over the past three years , -14% over the past five years .
You don't have any saved screeners yet
